Clinical and Radio-pathological Spectrum of Bone Tumors: Review and Update
<p>Bone tumors (BTs) range from benign to malignant and differ in pathogenesis according to the origin of the skeletal tissue, that is, osteogenic, chondrogenic, fibrogenic, vascular, osteoclastic giant cell-rich, hematopoietic neoplasm, notochordal, and other mesenchymal tumors of bone. The locatio...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2026
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/1237112 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | <p>Bone tumors (BTs) range from benign to malignant and differ in pathogenesis according to the origin of the skeletal tissue, that is, osteogenic, chondrogenic, fibrogenic, vascular, osteoclastic giant cell-rich, hematopoietic neoplasm, notochordal, and other mesenchymal tumors of bone. The location, site, and type of BT vary according to the age of the patient. The confirmatory diagnosis for malignant ones involves the combined radiological and histopathological approach, that is, radiograph, MRI, bone scan, tissue biopsy with gross specimen, microscopy, molecular biology, and immunohistochemistry (IHC). MRI is useful to assess the local extent and staging, recurrent/residual disease, and post-operative complications. CT is indicated to evaluate only few BT because of the ionizing radiation. Contrast CT chest and bone scans are indicated for metastatic work-up. Management ranges from a conservative approach, wide local excision, en bloc resection, limb salvage surgery/amputation to chemotherapy depending upon molecular markers and radiotherapy. In this chapter, authors shed the spotlight on BT, based on multi-modality and multidisciplinary collaborative pragmatic approach, with updates from current literature.</p> |
|---|---|
| ISBN: | 978-1-83635-977-7 |
| DOI: | 10.5772/intechopen.1013838 |